31 completed, 14 unknown, 7 terminated, 6 recruiting. 61 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 61 | Completed 31, Unknown 14, Terminated 7, Recruiting 6, Withdrawn 2, Not yet recruiting 1 |
Follow tocilizumab: new trials by email Literature Review of tocilizumab trials Research Report on tocilizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment Strategy for Patients With RA-ILD Tocilizumab, Rituximab (RTX), Methotrexate - Rheumatoid Arthritis Associated Interstitial Lung Disease | Phase 4 | Not yet recruiting | Chinese SLE Treatment And Research Group | 204 | 2026-09-20 | 2026-09-03 |
| Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) Linvoseltamab, Tocilizumab - Relapsed/Refractory Multiple Myeloma (RRMM) | Phase 4 | Recruiting | Regeneron Pharmaceuticals | 30 | 2026-07-15 | 2026-10-27 |
| A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy Tocilizumab(400mg) combined with Flupentixol Melitracen(0.5mg:10mg), Tocilizumab(400mg) - Thyroid-Associated Ophthalmopathy | Phase 4 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 60 | 2024-12-12 | 2025-04-16 |
| Plan Development for Giving Teclistamab in the Outpatient Setting Teclistamab, Tocilizumab - Multiple Myeloma, Relapsed Cancer | Phase 4 | Recruiting | University Health Network, Toronto | 15 | 2024-11-19 | 2025-12-10 |
| Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia Dexamethasone, Tocilizumab, Anakinra - Sepsis, Neuroinflammatory Response | Phase 4 | Unknown | Radboud University Medical Center | 52 | 2024-10-24 | 2025-04-04 |
| A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis Prednisone, Methotrexate, Tocilizumab - Takayasu Arteritis | Phase 4 | Recruiting | Shanghai Zhongshan Hospital | 124 | 2024-06-28 | 2024-10-17 |
| Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie Nivolumab, Pembrolizumab, Ipilimumab - Oncology, Infusion Reaction | Phase 4 | Recruiting | Isala | 1082 | 2023-09-01 | 2026-10-29 |
| COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure SGLT2i, beta blocker, ARNI, MRA, MTD, Education-First - Heart Failure | Phase 4 | Completed | Brigham and Women's Hospital | 503 | 2023-05-05 | 2026-02-06 |
| Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients Tocilizumab - Multiple Myeloma | Phase 4 | Unknown | The First Affiliated Hospital of Soochow University | 48 | 2023-04-17 | 2023-06-02 |
| Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics Bifidobacterium Bifidum Oral Capsule, Cisplatin, Carboplatin - Cancer Therapy-related Cardiovascular Toxicity | Phase 4 | Unknown | Peking University Third Hospital | 200 | 2023-02-15 | 2023-02-16 |
| Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS) Methylprednisolone, intravenous immunoglobulin, Tocilizumab - Severe Fever With Thrombocytopenia Syndrome | Phase 4 | Unknown | Qin Ning | 350 | 2022-08-19 | 2023-07-21 |
| High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19 Methylprednisolone, Tocilizumab - COVID-19 Virus Infection, Cytokine Storm | Phase 4 | Withdrawn | Marmara University | 2021-02-01 | 2021-11-24 | |
| Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients. Remdesivir, Hydroxychloroquine, Tocilizumab - Covid19, Pneumonia | Phase 4 | Unknown | October 6 University | 150 | 2020-10-01 | 2021-03-17 |
| A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis Tocilizumab, Glucocorticoids - Idiopathic Retroperitoneal Fibrosis | Phase 4 | Unknown | Peking Union Medical College Hospital | 40 | 2020-07-01 | 2021-03-22 |
| TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience Tocilizumab - Covid19 | Phase 4 | Completed | FMH College of Medicine and Dentistry | 93 | 2020-05-12 | 2021-01-29 |
| The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation Tocilizumab - Covid19 Pneumonia | Phase 4 | Unknown | Hadassah Medical Organization | 500 | 2020-04-08 | 2020-05-06 |
| A Pilot Study in Severe Patients With Takayasu Arteritis. Tocilizumab, Adalimumab - Takayasu Arteritis, Tocilizumab | Phase 4 | Recruiting | Shanghai Zhongshan Hospital | 40 | 2020-03-01 | 2021-08-10 |
| Use of Tocilizumab Drug Levels to Optimize Treatment in RA Tocilizumab - Rheumatoid Arthritis | Phase 4 | Unknown | Reade Rheumatology Research Institute | 98 | 2020-03-01 | 2024-04-18 |
| A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA) tacrolimus, methotrexate, adalimumab - Rheumatoid Arthritis (RA) | Phase 4 | Completed | Astellas Pharma Korea, Inc. | 21 | 2019-02-13 | 2024-10-31 |
| Therapeutic Drug Monitoring of Tocilizumab in Rheumatoid Arthritis Tocilizumab - Rheumatoid Arthritis, Tocilizumab | Phase 4 | Unknown | Tel-Aviv Sourasky Medical Center | 80 | 2018-12-01 | 2018-12-26 |
Showing 20 of 61. Sign in to see all of them.
Arthritis, Rheumatoid (37) · COVID-19 (3) · Cytokine Release Syndrome (3) · Multiple Myeloma (3) · Arthritis, Juvenile (2) · Giant Cell Arteritis (2) · Neoplasms (2) · Takayasu Arteritis (2) · Aortitis (1) · Arthritis (1) · Endotoxemia (1) · Graves Ophthalmopathy (1) · Heart Failure (1) · Neuroinflammatory Diseases (1) · Plaque, Atherosclerotic (1)
Hoffmann-La Roche (21) · Karolinska Institutet (2) · Massachusetts General Hospital (2) · Shanghai Zhongshan Hospital (2) · Assistance Publique - Hôpitaux de Paris (1) · Astellas Pharma Korea, Inc. (1) · Brigham and Women's Hospital (1) · Centre Hospitalier Régional d'Orléans (1) · Centre Hospitalier Universitaire de Besancon (1) · Chinese PLA General Hospital (1) · Chinese SLE Treatment And Research Group (1) · Dr. Larry W. Moreland (1) · FMH College of Medicine and Dentistry (1) · Genentech, Inc. (1) · Hadassah Medical Organization (1)
United States (12) · China (9) · France (8) · United Kingdom (7) · Italy (6) · Netherlands (6) · Spain (6) · Germany (5) · Israel (5) · Russia (5) · Finland (4) · Sweden (4) · Belgium (3) · Canada (3) · Greece (3)
Lindi Jiang, PhD (2) · Ronald van Vollenhoven, MD, Prof. (2) · Ahmed Tawakol, MD (1) · Aijaz Zeeshan Khan Chachar, MBBS,FCPS (1) · Ana D Fernandes, MA (1) · Christian Dejaco, MD, PhD (1) · Christine Chen, Dr. (1) · Dr Maya H Buch (1) · Eric Toussirot, Professor (1) · Gertjan Wolbink, MD, PhD (1)
PMID 28376912, PMID 14558057, PMID 22674883, PMID 23515142, PMID 24448345, PMID 25167216, PMID 25697557, PMID 26613768, PMID 26733110, PMID 27654603, PMID 28955499, PMID 29853455, PMID 29884223, PMID 31043095, PMID 31106666, PMID 31413865, PMID 31469238, PMID 32025629, PMID 32212002, PMID 32711802, PMID 32803573, PMID 32993784, PMID 33268527, PMID 33585031, PMID 34256800, PMID 34269927, PMID 34764044, PMID 36828925, PMID 37423647, PMID 37540159, PMID 37846618, PMID 37942714, PMID 38251564, PMID 38580350, PMID 39079894, PMID 40480650, PMID 40527572, PMID 41652651, PMID 41881637, PMID 41943506, PMID 42567558
2009 (3), 2014 (2), 2018 (1), 2023 (1)